Login to MyKarger

New to MyKarger? Click here to sign up.



Login with Facebook

Forgot your password?

Authors, Editors, Reviewers

For Manuscript Submission, Check or Review Login please go to Submission Websites List.

Submission Websites List

Institutional Login
(Shibboleth or Open Athens)

For the academic login, please select your country in the dropdown list. You will be redirected to verify your credentials.

Original Paper

Effect of Acetylcysteine on Experimental Corneal Wounds in Dogs

Aldavood S.J. · Behyar R. · Sarchahi A.A. · Rad M.A. · Noroozian I. · Ghamsari S.M. · Sadeghi-Hashjin G.

Author affiliations

Tehran University, Tehran, Iran

Related Articles for ""

Ophthalmic Res 2003;35:319–323

Do you have an account?

Login Information





Contact Information











I have read the Karger Terms and Conditions and agree.



Login Information





Contact Information











I have read the Karger Terms and Conditions and agree.



To view the fulltext, please log in

To view the pdf, please log in

Buy

  • FullText & PDF
  • Unlimited re-access via MyKarger
  • Unrestricted printing, no saving restrictions for personal use
read more

CHF 38.00 *
EUR 35.00 *
USD 39.00 *

Select

KAB

Buy a Karger Article Bundle (KAB) and profit from a discount!

If you would like to redeem your KAB credit, please log in.


Save over 20% compared to the individual article price.
Learn more

Rent/Cloud

  • Rent for 48h to view
  • Buy Cloud Access for unlimited viewing via different devices
  • Synchronizing in the ReadCube Cloud
  • Printing and saving restrictions apply

Rental: USD 8.50
Cloud: USD 20.00


Select

Subscribe

  • Access to all articles of the subscribed year(s) guaranteed for 5 years
  • Unlimited re-access via Subscriber Login or MyKarger
  • Unrestricted printing, no saving restrictions for personal use
read more

Subcription rates


Select

* The final prices may differ from the prices shown due to specifics of VAT rules.

Article / Publication Details

First-Page Preview
Abstract of Original Paper

Received: July 08, 2002
Accepted: May 27, 2003
Published online: December 29, 2003
Issue release date: November – December

Number of Print Pages: 5
Number of Figures: 4
Number of Tables: 1

ISSN: 0030-3747 (Print)
eISSN: 1423-0259 (Online)

For additional information: https://www.karger.com/ORE

Abstract

The effects of 3, 10 and 20% concentrations of acetylcysteine on experimental corneal wound healing in dogs were evaluated. Experimental corneal wounds were induced surgically, up to the depth of the anterior third of the stroma, in both eyes of 18 dogs. One of the eyes was treated topically with 0.9% NaCl solution three times a day. The contralateral eye was treated topically with acetylcysteine (3, 10 and 20% concentrations) in each of 6 cases separately. Corneal wounds were measured by fluorescein staining every day. The mean time of healing in the 3% group was significantly different from control eyes (6.17 ± 1.94 days). It was 7.19 ± 0.75 days in the 20% group and 7 ± 2 days in the 10% group. The last two groups were not significantly different from the controls (9.67 ± 3.01 days and 8.17 ± 3.60 days, respectively).

© 2003 S. Karger AG, Basel


References

  1. Ziment I: Acetylcysteine: A drug that is much more than a mucokinetic. Biomed Pharmacother 1988;513:520–542.
  2. Webb WR: Clinical evaluation of a new mucolytic agent acetylcysteine. J Thorac Cardiovasc Surg 1962;44:330–335.
  3. Sheffner AL: The reduction in vitro in viscosity of mucoprotein solutions by a new mucolytic agent, N-acetyl-L-cysteine. Ann NY Acad Sci 1963;106:299–304.
  4. Absolon MJ, Brown CA: Acetylcysteine in kerato-conjunctivitis sicca. Br J Ophthalmol 1968;52:310–316.
  5. Slansky HH, Berman MB, Dohlman CH, Rose J: Cysteine and acetylcysteine in the prevention of corneal ulcerations. Ann Ophthalmol 1970;2:488–493.
  6. Haut J, Labrune P, Ullern M: New trial treatment of dry eye with acetylcysteine ophthalmic solution. Bull Soc Ophthalmol Fr 1977;77:165–167.
  7. Brown SI, Weller CA: Collagenase inhibitors in prevention of ulcers alkali-burned cornea. Arch Ophthalmol 1970;83:352–353.
  8. Brown SI, Tragakis M, Pearce D: Treatment of the alkali-burned cornea. Am J Ophthalmol 1972;74:316–320.
  9. Williamson J, Doig WM, Forrester JV, Tham MH, Wilson T, Whaley K, Carsondick W: Management of the dry eye in Sjögren’s syndrome. Br J Ophthalmol 1974;58:798–805.
  10. Franke G, Wilhelm F, Deutschmann S, Pedal W: Experiences with a new corneal suction trephine. Acta Ophthalmol 1989;67:597–600.
  11. Berman MB: Collagenase inhibitors: Rationale for their use in treating corneal ulceration. Int Ophthalmol Clin 1975;15:49–66.
  12. Frauenfelder FT, Wright P, Tripathi RC: Corneal mucus plaques. Am J Ophthalmol 1977;83:191–197.
  13. Marsh RJ, Cooper M: Ophthalmic zoster: Mucous plaque keratitis. Br J Ophthalmol 1987;71:725–728.
  14. Obenberger J, Cejkova J: Corneal damage following intracorneal injection of N-acetyl-L-cysteine. Albrecht von Graefes Arch Klin Exp Ophthalmol 1972;285:171–176.
  15. Petroutsos G, Guimaraes R, Giraud JP, Renard G, Pouliquen Y: Effect of acetylcysteine (Mucomyst) on epithelial wound healing. Ophthalmic Res 1982;14:241–248.
  16. Sugar A, Waltman SR: Corneal toxicity of collagenase inhibitors. Invest Ophthalmol 1973;12:779–782.
  17. Nichols BA, Chiappino L, Dawson CR: Demonstration of the mucous layer of the tear film by electron microscopy. Invest Ophthalmol Vis Sci 1985;26:464.
  18. Draeger J, Hackelbusch R: Experimentelle Untersuchungen und klinische Ergebnisse mit neuen Rotorinstrumenten. Ophthalmologica, 1972;164:273–283.
  19. Fitton JH, Ziegelaar BW, Hicks CR, Clayton AB, Crawford GJ, Constable IJ, Chirila TV: Assessment of anticollagenase treatments after insertion of a keratoprosthetic material in the rabbit cornea. Cornea 1998;17:108–114.
  20. Brown SI, Akia S, Weller CA: Prevention of the ulcers of the alkali-burned cornea: Preliminary studies with collagenase inhibitors. Arch Ophthalmol 1969;82:95–97.
  21. Berman M, Dohlman C: Collagenase inhibitors. Arch Ophthalmol Rev Gen Ophthalmol (Paris) 1975;35:95–112.
  22. Berman M, Manable R: Corneal collagenases: Evidence for zinc metalloenzymes. Ann Ophthalmol 1973;5:1193–1195.
  23. Kanao S, Kouzuki S, Isuneno M, Enomoto H, Yasuhiro K, Yamane Y: Clinical application of 3% N-acetylcysteine eye drops in corneal diseases in dogs. J Japan Vet Med Assoc 1993;46:488–491.
  24. Burns FR, Stack MS, Gray RD, Paterson CA: Inhibition of purified collagenase from alkali-burned rabbit corneas. Invest Ophthalmol Vis Sci 1989;30:1569–1575.
  25. Therms F, Molon-Noblot S, Grove J: Effects of acetylcysteine on rabbit conjunctival and corneal surfaces. Invest Ophthalmol Vis Sci 1991;32:2958–2963.
  26. Chen HB, Yamabayashi S, Ou B, Tanaka Y, Ohno S, Tsukahara S: Structure and composition of rat precorneal tear film. A study by an in vivo cryofixation. Invest Ophthalmol Vis Sci 1977;38:381–387.

Article / Publication Details

First-Page Preview
Abstract of Original Paper

Received: July 08, 2002
Accepted: May 27, 2003
Published online: December 29, 2003
Issue release date: November – December

Number of Print Pages: 5
Number of Figures: 4
Number of Tables: 1

ISSN: 0030-3747 (Print)
eISSN: 1423-0259 (Online)

For additional information: https://www.karger.com/ORE


Copyright / Drug Dosage / Disclaimer

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.